Name: Cartalax 50mg
Availability: InStock

The Novera Compounds Advantage

Made in the USA

Manufactured in the United States under controlled standards. Reliable production. Dependable supply. No overseas uncertainty.

High Purity — 99% or Better

Every batch meets ≥99% purity specifications and is verified by independent third-party laboratory testing. Clean. Consistent. Documented.

Advanced Lyophilized Stability

Carefully lyophilized for structural integrity and easier handling. No cold shipping required. No dry ice. No complications.

Designed for Research

Ideal for scientific study, analytical testing, and research workflows where consistency and quality matter most.

Smart Pricing. Real Value.

High purity. USA-made. Third-party tested. Priced to make sense.

Everything in One Order

Already ordering other products? Add peptides to the same shipment. One vendor. One contact person. Simple.

Product Description

Specifications

Description

Strength: 50mg
CAS: N/A
Chemical Formula: C₁₂H₁₉N₃O₈
Molecular weight: 333.29 g/mol
Peptide Sequence: Ala-Glu-Asp
Synonyms: AED peptide
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

Cartalax (50mg) About This Product

The Cartalax peptide is a synthetic tripeptide bioregulator composed of the peptide sequence Ala–Glu–Asp. Laboratories that buy Cartalax peptide or order Cartalax peptide materials reference this compound for controlled laboratory research involving peptide–cell interactions and connective tissue–related experimental models. Cartalax originates from Russian peptide bioregulation research associated with the St. Petersburg Institute of Bioregulation and Gerontology, where short peptides have been studied in tissue-specific cellular systems.

Cartalax is structurally homologous to regions of type XI collagen, a component of connective tissue. This structural similarity underlies its use in laboratory studies involving chondrocytes and fibroblasts. In experimental settings, Cartalax has been examined for direct interaction with nuclear components in cell culture models, without reliance on membrane receptor signaling.

The AEDR peptide product is supplied as a lyophilized powder in 50 mg sterile glass vials, commonly verified to ≥98% purity by HPLC, and intended exclusively for controlled laboratory research.

Product Specifications

Chemical Formula: C₁₂H₁₉N₃O₈
Molecular Weight: 333.29 g/mol
Form: Lyophilized powder
Vial Size: 50 mg sterile glass vial

Cartalax (50mg) Key Features and Benefits

Chemical identity: Tripeptide (AED) composed of three amino acids
Purity: Commonly produced at ≥98%, verified by HPLC
Non-hormonal profile: Evaluated without involvement of endocrine signaling pathways
Research focus: Studied in laboratory models involving connective tissue cell cultures
Cellular research scope: Examined in experimental systems related to structural maintenance and cellular stress response
Format: Supplied as a lyophilized powder for laboratory handling and storage
Research compatibility: Suitable for controlled in vitro studies alongside other short regulatory peptides

For laboratory research use only.

Cartalax (50mg) Mechanism & Research Applications

Cartalax has been studied in laboratory research as a tissue-associated peptide examined for its interaction with intracellular regulatory processes in cell culture systems. Rather than acting through membrane receptors, it has been evaluated in experimental models examining peptide effects on nuclear and transcriptional activity.

Research applications include:

Connective tissue cell culture studies involving chondrocytes and fibroblasts
Cellular aging model investigations examining senescence-associated markers in vitro
Extracellular matrix research models focused on structural protein regulation
Renal and dermal cell culture systems used for comparative peptide studies

All applications described reflect controlled laboratory research contexts and do not imply clinical or therapeutic use.

Cartalax (50mg) Dosing & Observed Effects in Research

Experimental dosing of Cartalax varies by study design and assay type. In vitro research commonly evaluates concentrations between 0.1 and 1.0 μg/mL, with incubation periods adjusted according to theexperimental endpoints.

Historical animal studies from early bioregulator research describe low-microgram dosing over defined timeframes. Contemporary research primarily focuses on in vitro experimental models rather than in vivo administration.

Reported laboratory observations include changes in gene expression profiles, cell proliferation markers, and assay-specific molecular readouts. These findings are derived exclusively from controlled research environments and do not indicate safety, efficacy, or clinical relevance.

Cartalax (50mg) Storage, Safety & References

Store lyophilized vials at ≤ –20 °C for long-term stability
Optimal long-term storage at –80 °C
Store at room temperature during transport or shipping
Keep vials sealed, dry, and protected from light
Allow vials to equilibrate to room temperature before opening
Reconstitute only with bacteriostatic water
Store reconstituted solutions at 2–8 °C, aliquot as needed, and avoid repeated freeze-thaw cycles
Mix gently to preserve peptide integrity

Dispose of unused material according to institutional laboratory guidelines.

References

https://pubmed.ncbi.nlm.nih.gov/19902107/

https://pubmed.ncbi.nlm.nih.gov/27909961/

https://pubmed.ncbi.nlm.nih.gov/27259496/

https://pubmed.ncbi.nlm.nih.gov/32160428/

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.

Reviews

There are no reviews yet.

Be the first to review “Cartalax 50mg”

You must be logged in to post a review.

Cartalax 50mg